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Received August 15, 2014; accepted December 6, 2014AbstractBackground: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare malignancy that has been reported in young individuals, especially
young women. Patients with PMBCL commonly receive rituximab induction. This single-institution study was designed to analyze the clinical
benefits of rituximab induction and its impact on postinduction treatments (PITs), especially radiotherapy.
Methods: The benefits of rituximab induction were evaluated by complete response (CR), early treatment failure, relapse, and overall survival
(OS) rates. The impact of the induction therapy on the adoption of PIT was evaluated by the proportion of patients who had received at the last
follow up any PIT modality [i.e., radiotherapy or hematopoietic stem cell transplantation (HSCT)], radiotherapy alone, HSCT alone, or both
modalities.
Results: Between 1999 and 2012, 48 PMBCL patients (29 men, 60%) were identified; they had a median age of 31 years. Twenty-eight patients
received rituximab induction; of these, 23 (82%) patients also underwent fludeoxyglucose-positron emission tomography (FDG-PET) evaluation.
Rituximab induction was significantly associated with higher rates of CR and OS, and lower rates of early treatment failure and relapse.
Regarding PIT, patients with rituximab induction were more likely to receive radiotherapy alone [with rituximab induction (25%) vs. without
rituximab induction (5%)], and patients with FDG-PET evaluation were similarly more likely to receive radiotherapy alone [with FDG-PET
evaluation (28.6%) vs. without FDG-PET evaluation (0%)]. In multivariate analysis, age older than 60 years [hazard ratio (HR), 16.697;
95% confidence interval (CI), 1.106e252.022; p ¼ 0.042] and rituximab induction (HR, 0.089; 95% CI, 0.012e0.653; p ¼ 0.017) were
significantly associated with OS.
Conclusion: Rituximab improved the CR and OS rates of patients with PMBCL, but these improvements may be attributable to the increased use
of radiotherapy (which may have also resulted from FDG-PET evaluation).
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401S.-H. Yang et al. / Journal of the Chinese Medical Association 78 (2015) 400e4071. Introduction mass were identified and reclassified as having PMBCL, ac-Primary mediastinal large B-cell lymphoma (PMBCL) is a
relatively rare malignancy, and accounts for only 2% of all
cases of non-Hodgkin's lymphoma (NHL).1 In comparison to
patients who have diffuse large B-cell lymphoma, not other-
wise specified (abbreviated as DLBCL hereafter), patients
with PMBCL are reportedly younger at diagnosis and pre-
dominantly female.1 Regarding chemotherapy induction ther-
apy, several large-scale analyses in Western countries have
shown that the third-generation chemotherapy regimen meth-
otrexate with leucovorin rescue, doxorubicin, cyclophospha-
mide, vincristine, prednisone, and bleomycin (MACOP-B) is
associated with a higher response rate2; however, cyclophos-
phamide, doxorubicin or epirubicin, vincristine, and predni-
sone every 21 days (CHOP-21) is commonly used in Asian
countries.3e6 In addition, the disease may be controlled further
by postinduction treatments (PIT) such as radiotherapy7 and/or
high-dose therapy plus autologous hematopoietic stem cell
transplantation (HSCT).8,9
Since the 2000s, rituximab and fludeoxyglucose-positron
emission tomography (FDG-PET) have been commonly used
in the management of B-cell NHL, which includes PMBCL.
Several recent reports have demonstrated that the addition of
rituximab in induction therapy (hereafter referred to as ritux-
imab induction) is associated with improved rates of response
and progression-free survival.10,11 Fludeoxyglucose-positron
emission tomography is usually employed to decide whether
these patients should receive additional radiotherapy, espe-
cially for patients who have possible residual or recurrent le-
sions in the mediastinum.12,13 However, Dunleavy et al14
demonstrated in their Phase II trial of the combination of
dose-adjusted etoposide, prednisone, Oncovin (vincristine),
cyclophosphamide, and hydroxydaunorubicin (doxorubicin)
(EPOCH) and rituximab (DA-EPOCH-R) that end-of-
treatment FDG-PET evaluation of PMBCL patients had a
relatively low positive predictive rate (17%), based on the
pathological findings of PET-positive lesions.14 In a nontrial
setting, the rate of biopsy for this malignancy is low, and it is
therefore anticipated that the use of radiotherapy will increase
for PMBCL, especially after rituximab-containing immu-
nochemotherapy. In the current study, we capitalized on our
experience of patients with PMBCL and performed a single-
institution investigation of rituximab's clinical benefits, as
evaluated by treatment response, relapse, and survival.
Furthermore, we sought to illustrate the evolution of PIT after
the adoption of rituximab induction.
2. Methods2.1. PatientsWe reviewed the records of patients who had B-cell NHL
and had been admitted to our hospital between 1999 and 2012.
All patients with the mediastinum as the primary site of the
neoplastic growth, as detected on computed tomography (CT),
and a pathological diagnosis of DLBCL for the mediastinalcording to the 2008 World Health Organization (WHO) clas-
sification.1 After excluding two identified patients who did not
receive treatment at our hospital, 48 patients were enrolled in
the present study. Information was collected regarding clinical
features at diagnosis, treatments, and outcomes at the latest
follow up (as of November 2013). This retrospective study was
approved by the Institutional Review Board of our hospital.
The clinical features that were analyzed included age, sex,
performance status [according to the Eastern Cooperative
Oncology Group (ECOG) scale], specific symptoms, serum
lactate dehydrogenase (LDH) levels, involvement of extra-
nodal sites (e.g., bone marrow), and clinical stage. In regard to
specific symptoms at diagnosis, superior vena cava (SVC)
syndrome was defined by imaging evidence of the SVC
encased by neoplastic growth plus the presence of clinical
symptoms such as facial swelling, chest discomfort, or su-
perficial vein engorgement over the anterior chest wall. Pa-
tients in which the greatest dimension of the mediastinal tumor
measured >10 cm were defined as having bulky disease.
Disease stages were defined according to the Ann Arbor sys-
tem, and patients who had lesions that were limited to above
the diaphragm with pleural effusion or pericardial effusion
were defined as having stage IIE disease, if no lymphoma cells
were found in the effusion. In addition, International Prog-
nostic Index (IPI) scores were calculated according to the
published criteria.152.2. TreatmentsInduction treatment consisted of chemotherapy with 6e8
cycles of the CHOP-21 regimen and (since 2005) CHOP-21
and rituximab (R-CHOP-21).
Postinduction treatment was defined as radiotherapy and
HSCT in the consolidation or salvage setting. Consolidation
PIT was administered if the response to treatment was less
than a complete response (CR) or was an unconfirmed com-
plete response (CRu) after induction and/or if negative prog-
nostic factors that indicated an elevated risk of relapse (e.g.,
bulky disease or poor IPI score) had been identified at diag-
nosis, as determined at the discretion of the physicians
involved. Salvage PITwas usually administered for relapsed or
refractory disease.
Radiotherapy was generally administered whenever any
questionable or definite residual lesion was found in the
mediastinum after the induction or salvage therapy. The
mobilization of peripheral blood stem cells was performed
after chemotherapy with second-line regimens [e.g., etoposide,
methylprednisolone, high-dose cytarabine, and cisplatin
(ESHAP)]. The main preparative regimens of HSCT were
busulfan, etoposide, cytarabine, and cyclophosphamide
(BEAC) and busulfan, etoposide, cytarabine, and melphalan
(BEAM). Autologous HSCT was usually performed as
consolidation or salvage therapy for patients with a response to
chemotherapy using second-line regimens, and allogeneic
HSCTwas only considered for patients with refractory disease
after chemotherapy using second-line regimens.
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after every 3e4 cycles of induction therapy and after 2e3
cycles of salvage chemotherapy, prior to and after radio-
therapy and HSCT, and/or whenever there was clinical evi-
dence of poor response or relapse. Complete response, CRu,
partial response (PR), and progressive disease (PD) were
defined according to previously reported criteria,16,17 and were
adjusted according to whether FDG-PET had been used, which
was determined at the discretion of the physicians involved.2.4. End pointsThe primary end point of the present study was the clinical
benefit of rituximab induction, which was evaluated by the
differences between the response, early treatment failure
(ETF), relapse, and overall survival (OS) rates of patients who
had and had not received rituximab induction. Patients with
PMBCL were classified as having ETF if they had experienced
a slow or inadequate response to 2e3 cycles of induction
therapy (determined according to the discretion of the physi-
cians) and had received chemotherapy with second-line regi-
mens earlier. Hence, the definition of ETF was modified from
previous definitions,11 which include (1) early death during
induction chemotherapy, (2) premature treatment withdrawal
as a result of stable disease (SD) and switch to salvage therapy,
and (3) PD or relapse within 6 months from treatment initia-
tion or within 4 weeks from the end of chemotherapy (prior to
or at postchemotherapy restaging). The OS was measured
from the time of diagnosis to the date of death from any cause
or the time of the last follow up.Table 1
The clinical features of 48 patients with primary mediastinal large B-cell lymphom
Parameters No. of cases (%)
Total 48 (100)
Sex Male/female 29 (60)/19 (40)
Age (y) Median (range) 31 (16e85)
>60 y 8 (17)
ECOG PS
0e2 38 (79)
3e4 10 (21)
B symptoms Yes 12/47 (26)
SVC syndrome Yes 21/47 (45)
Pleural/pericardial/effusion Yes 30/46 (65)
Bulky disease Yes 23/45 (51)
Marrow involvement Yes 3 (6)
Ann Arbor stage
I and II 35 (73)
III and IV 13 (27)
Serum LDH >ULN 38/45 (84)
IPI score
0e1 20/45 (45)
2e3 24/45 (53)
4e5 1/45 (2)
ECOG ¼ Eastern Cooperative Oncology Group; IPI ¼ International Prognostic Ind
vena cava; ULN ¼ upper limit of normal.
a ManneWhitney U test.
b Fisher's exact test.The secondary end point of the study was the relevance of
rituximab induction to the evolution of PIT in patients with
PMBCL. The evolution of PIT was evaluated by the pro-
portions of patients who had received any PIT modality by the
time of the last follow up. The PIT modalities were classified
as either radiotherapy alone, HSCT alone, or the combination
of both modalities. In addition, because rituximab and FDG-
PET were applied at fairly similar times during the clinical
care of patients with PMBCL, we also examined the impact of
FDG-PET on the evolution of PIT. We analyzed the associa-
tions of PIT with rituximab induction and FDG-PET evalua-
tion separately because patients receiving rituximab did not
always undergo FDG-PET. We assumed that the decision to
administer PIT could only have depended on FDG-PET find-
ings in the patients who received FDG-PET during the treat-
ment and during the follow-up period. For conciseness, the
term “FDG-PET evaluation” is employed in this manuscript to
describe patients with FDG-PET evaluations during treatment
and during follow up.2.5. Statistical analysisAll statistical analyses were performed using SPSS for
Windows v. 17.0 (SPSS Inc., Chicago, IL, USA). Categorical
variables were compared using the Pearson c2 test or the
Fisher's exact test, whereas continuous variables were
compared using the t test or the ManneWhitney rank-sum test.
The KaplaneMeier method was used to estimate the OS, and
the log-rank test was used to compare the survival of patients
with different prognostic factors and treatments. Multivariate
Cox proportional hazards regression analysis was used to
identify factors that were independently associated with OSa, according to rituximab induction.
Without rituximab, n (%) With rituximab, n (%) p
20 (100) 28 (100)
13 (65)/7 (35) 17 (61)/11 (39) >0.99
30 (17e84) 31 (16e85) >0.99a
4 (20) 4 (14)
0.16b
18 (90) 20 (71)
2 (10) 8 (29)
4/19 (21) 8 (29) 0.414
8/19 (42) 13 (46) 0.469
13/19 (68) 17/27 (63) 0.902
10/17 (59) 13 (46) 0.542
3 (15) 0 0.066
0.110
12 (60) 23 (82)
8 (40) 5 (18)
15/17 (88) 23 (82) 0.693
0.410
6/17 (35) 14 (50)
11/17 (65) 13 (46)
0/17 (0) 1 (4)
ex; LDH ¼ lactate dehydrogenase; PS ¼ performance status; SVC ¼ superior
Table 2
The responses, postinduction treatments, and outcomes of 48 patients with primary mediastinal large B-cell lymphoma, according to rituximab induction.
Parameters Total, n (%) Without rituximab, n (%) With rituximab, n (%) p
Total 48 (100) 20 (100) 28 (100)
FDG-PET evaluation 28 (58) 5 (25) 23 (82) <0.001
Response rates to first induction CR/CRu 34 (71) 10 (50) 24 (86) 0.024
PR, SD, PD 9 (19) 6 (30) 3 (11)
Not evaluable 5 (10) 4 (20) 1 (4)
Early treatment failure 16 (33) 13 (65) 3 (11) <0.001
Early death 4 (8) 3 (15) 1 (4)
Premature treatment withdrawal 4 (8) 4 (20) 0
Early PD or relapse 8 (17) 6 (30) 2 (7)
Radiotherapy Consolidation 12 (25) 1 (5) 11 (39) 0.001
Salvage 9 (19) 8 (40) 1 (4)
HSCT Consolidation 9 (19) 2 (10) 7 (25) 0.004
Salvage 16 (33) 12 (60) 4 (14)
Relapse 7/34 (21) 5/10 (50) 2/24 (8) 0.014
Alive at last follow-up 36 (75) 11 (55) 25 (89)
Mean OS (mo)a 113.9 88.5 90.9 0.011
Cause of death 12 9 3
Lymphoma 3 2 1
Infection 9 7 2
CR ¼ complete response; CRu ¼ unconfirmed complete response; FDG-PET ¼ fludeoxyglucose-positron emission tomography; HSCT ¼ hematopoietic stem cell
transplantation; OS ¼ overall survival; PD ¼ progressive disease; PR ¼ partial response; SD ¼ stable disease.
a The median OS was not achieved for either subgroup.
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factors that had p < 0.1 in univariate analyses. For all analyses,
p < 0.05 was considered statistically significant.
3. Results3.1. Clinical characteristics at diagnosis, according to
rituximab induction therapyForty-eight patients were included in our analysis [29
(60%) males; median age, 31 years; range, 16e85 years; Table
1]. Eight (17%) patients were older than 60 years. At diag-
nosis, symptoms of SVC syndrome and a bulky mass were
present in 21 (45%) of 47 patients and in 27 (60%) of 45
patients, respectively. Thirty-eight (84%) of 45 patients had
elevated serum LDH levels. Thirteen (27%) patients had
advanced stages (III or IV) of disease, 25 (55%) of 45 patients
had an intermediate-to-high IPI score (i.e., 2) at diagnosis,
and 28 (58%) patients received rituximab induction. Patients
with and without rituximab induction had similar de-
mographics (Table 1).Table 3
Distribution of postinduction treatments, according to the classification of rituxim
Rituximab in
No. of patients No (%) Yes (%
Total 20 (100) 28 (10
Any PIT Yes 15 (75) 18 (64
PIT modality
Radiotherapy alone 1 (5) 7 (25)
HSCT alone 6 (30) 6 (21.
Both 8 (40) 5 (17.
FDG-PET ¼ fludeoxyglucose-positron emission tomography; HSCT ¼ hematopoi
a Fisher's exact test.3.2. Postinduction treatment and outcomes, according to
rituximab induction therapyIn comparison to their counterparts, patients with rituximab
induction were more likely to have undergone FDG-PET for
response evaluations (25% vs. 82%, respectively; p < 0.001;
Table 2). In addition, rituximab induction was associated with
significantly higher CR/CRu rates [86% (with rituximab) vs.
50% (without rituximab), p ¼ 0.024] and lower ETF rates
[11% (with rituximab) vs. 65% (without rituximab),
p < 0.001]. The lower ETF rate in patients with rituximab
induction reflected the combination of differences in early
death rates [with vs. without rituximab induction (4% vs. 15%,
respectively)], premature treatment withdrawal rates (0% vs.
20%, respectively), and early PD or relapse rates (7% vs. 30%,
respectively).
With regard to PIT modalities (Table 2), the proportion of
cases that included radiotherapy was similar in patients with
and without rituximab induction (43% vs. 45%, respectively),
whereas patients with rituximab induction were more likely to
have received radiotherapy as a consolidation therapy becauseab induction or FDG-PET evaluation.
duction FDG-PET evaluation
) p No (%) Yes (%) p
0) 20 (100) 28 (100)
.3) 0.535a 11 (55) 22 (78.6) 0.117a
0.128 0.03
0 (0) 8 (28.6)
4) 4 (20) 8 (28.6)
9) 7 (35) 6 (21.4)
etic stem cell transplantation; PIT ¼ postinduction treatment.
Fig. 1. The overall survival of patients with primary mediastinal large B-cell
lymphoma, according to the use of rituximab induction.
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(39% vs. 5%, p < 0.001). In addition, patients with rituximab
were less likely to have received HSCT (43% vs. 70%,
p ¼ 0.014), and HSCTwas used as a consolidation therapy in a
higher proportion of these patients. Of the 25 patients who
received HSCT once, seven (28%) patients received allogeneic
HSCT as salvage therapy, which included three patients who
received autologous HSCT.3.3. Distribution of PIT, according to classification of
rituximab induction or FDG-PET evaluationBecause many patients who received rituximab induction
also underwent FDG-PET for the evaluation of PMBCL, we
further investigated the use of PIT according to rituximab in-
duction and the FDG-PET evaluation status. As Table 3 shows,Table 4
Prognostic factors for overall survival in 48 patients with primary mediastinal larg
Parameters
Sex Male vs. female
Age (y) >60 vs. 60
ECOG PS 2e4 vs. 0e1
B symptoms Yes vs. no
SVC syndrome Yes vs. no
Pericardial/pleural effusion Yes vs. no
Bulky disease Yes vs. no
Marrow involvement Yes vs. no
Ann Arbor stage III/IV vs. I/II
LDH >ULN vs. ULN
IPI (score) High (4e5) vs. intermediate (2e3) vs. low (0e1)
Rituximab induction Yes vs. no
Any PIT Yes vs. no
Radiotherapy Yes vs. no
HSCT Yes vs. no
CI ¼ confidence interval; ECOG ¼ Eastern Cooperative Oncology Group;
IPI ¼ International Prognostic Index; LDH ¼ lactate dehydrogenase; PIT ¼ pos
ULN ¼ upper limit of normal.we found that FDG-PET evaluation was significantly associ-
ated with the distribution of PIT ( p ¼ 0.03). In comparison to
patients who did not undergo FDG-PET evaluation, a higher
proportion of the patients who underwent FDG-PET evalua-
tion received radiotherapy alone, whereas a lower proportion
received both radiotherapy and HSCT. A similar trend was
observed for rituximab induction (Table 3).3.4. Survival and prognostic factorsThe median duration of follow up was 67.2 months (range,
7.1e150 months). At last follow up, 36 (75%) patients were
alive and disease-free. The 3-year OS rate was 73%. Patients
with rituximab induction had a better mean duration of OS
than patients without rituximab induction (90.9 months vs.
88.5 months, respectively, p ¼ 0.011; Table 2 and Fig. 1). The
causes of death included uncontrolled lymphoma in three
patients, and treatment-related neutropenia and infection in
nine patients (Table 2).
As Table 4 shows, we evaluated the univariate relationships
between several factors and OS. Factors that were associated
with poor OS included age older than 60 years, the presence of
SVC syndrome, in a high IPI risk group at diagnosis, the
absence of rituximab induction, and the absence of any PIT.
When all factors with p < 0.1 (except for the IPI risk group)
were included in the multivariate Cox regression analysis, age
older than 60 years [hazard ratio (HR), 16.697; 95% CI,
1.106e252.022; p ¼ 0.042] and rituximab induction (HR,
0.089; 95% CI, 0.012e0.653; p ¼ 0.017) were independent
prognostic factors for OS. Furthermore, SVC syndrome at
diagnosis tended to be associated with poor OS.
4. Discussion
Based on clinical experiences at a single institution, this
study's findings demonstrated the clinical benefits of rituximabe B-cell lymphoma.
Univariate Multivariate
HR 95% CI p HR 95% CI p
1.707 0.462e6.315 0.423 d d d
6.840 2.187e21.388 0.001 16.697 1.106e252.022 0.042
3.414 0.747e15.613 0.113 d d d
1.912 0.999e3.661 0.05 0.268 0.015e4.883 0.374
4.359 1.153e16.488 0.03 3.867 0.431e34.665 0.227
1.405 0.685e2.884 0.345 d d d
1.681 0.947e2.983 0.076 4.844 0.378e62.077 0.225
4.230 0.910e19.666 0.066 1.179 0.087e16.034 0.901
1.384 0.416e4.602 0.596 d d d
1.841 0.931e3.642 0.079 0.806 0.057e11.318 0.873
4.641 1.495e14.413 0.008 d d d
0.213 0.057e0.787 0.020 0.089 0.012e0.653 0.017
0.218 0.061e0.785 0.020 0.172 0.017e1.687 0.131
0.796 0.253e2.511 0.697 d d d
0.553 0.175e1.746 0.313 d d d
HR ¼ hazard ratio; HSCT ¼ hematopoietic stem cell transplantation;
tinduction treatments; PS ¼ performance status; SVC ¼ superior vena cava;
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ciations between rituximab induction and PIT; rituximab in-
duction was particularly associated with the increased use of
radiotherapy alone. When administered to patients with
PMBCL, rituximab induction improved the CR/CRu and OS
rates, and reduced the ETF and relapse rates. These findings
are similar to the results of several recent studies.5,10,11,18
Furthermore, rituximab induction was associated with
greater use of radiotherapy as a consolidation therapy rather
than as salvage therapy (Table 3), although the proportion of
PMBCL patients who finally received radiotherapy was
similar with and without rituximab induction (45% vs. 43%,
respectively; Table 2). In fact, the proportion of our patients
who received radiotherapy may have been reduced because of
the early adoption of front-line HSCT. Several recent studies
have demonstrated trends of increased radiotherapy use in
PMBCL patients who received rituximab induction. Among
German patients with PMBCL, radiotherapy was slightly more
common in patients with rituximab (73%) than in patients
without rituximab (67%).10 The proportion of Greek patients
undergoing radiotherapy was similarly greater among patients
with rituximab (70%) than among patients without rituximab
(48%).11 The proportion of patients undergoing radiotherapy
further increased to 89% in a report by the International
Extranodal Lymphoma Study Group (IELSG).19
Our present results, and those of the aforementioned
studies, showed that most patients with PMBCL experienced a
good treatment response after induction therapy with R-
CHOP-21 and received radiotherapy because CT or FDG-PET
scans showed an avid residual lesion in the mediastinum.
These findings have positive and negative implications. First,
R-CHOP-21 alone is insufficient as a means of fully control-
ling PMBCL.20 It is possible that FDG-PET improves the
detection of small residual lesions in the mediastinum, which
could explain the greater administration of radiotherapy in the
patients with PMBCL who underwent FDG-PET. However,
radiotherapy may be unnecessary in some patients with
PMBCL, as shown in the study of DA-EPOCH-R by Dunleavy
et al.14 Furthermore, radiotherapy did not confer a benefit in
the OS of PMBCL patients with or without rituximab in our
study or in several previous studies.10,11
Rituximab induction and subsequent FDG-PET evaluation
have probably contributed to the increased use of radiotherapy
in patients with PMBCL. Our attempts to weigh the individual
influences of rituximab induction and FDG-PET evaluation
were limited by their fairly similar application times and the
relatively small number of patients in this study. The findingsTable 5
Comparison of reported sex distributions for patients with primary mediastinal lar
Study, author (year) Country/region Calendar peri
Zinzani (2002)12 Europe 1981e1999
Savage (2006)30 Canada 1980e2003
Hamlin (2005)28 United States of America 1980e1999
Sekiguchi (2004)3 Japan 1982e2002
Ahn (2010)4 Korea 1995e2009
Current study (2014) Taiwan 1999e2012of several recent studies have nonetheless supported this the-
ory. Han et al21 and Avivi et al22 report that rituximab in-
duction in DLBCL patients is associated with higher false-
positive rates by FDG-PET, compared to the false-positive
rates of FDG-PET in DLBCL patients without rituximab in-
duction. This is possibly a consequence of immune-mediated
inflammation. Pregno et al23 showed that interim FDG-PET
failed to predict the outcomes of DLBCL in patients treated
with R-CHOP, and Avigdor et al24 showed that interim FDG-
PET failed to predict the outcomes of PMBCL in patients after
R-VACOP-B and R-CHOP-21. Most importantly, Dunleavy
et al14 clearly demonstrated by aggressively performing bi-
opsies that end-of-treatment FDG-PET had a relatively high
false-positive rate after DA-EPOCH-R therapy. Because pa-
tients with PMBCL are usually relatively young, radiotherapy
of the mediastinum is potentially associated with long-term
sequelae, as seen in patients with Hodgkin disease.25,26 The
Deauville 5-point criteria has increasingly been used to
interpret FDG-PETepositive residual lesions in the medias-
tinum after rituximab induction.27 This approach will provide
a basis for using PET/CT to define the role of radiotherapy in
PMBCL.19
Another interesting finding of our study was the predomi-
nance of male patients in our study cohort. This finding con-
trasts with most studies from Western countries,12,28 whereas
several reports from China,29 Japan,3 Canada,30 and from
other hospitals in Taiwan31,32 show findings that are similar to
our own (Table 5).3,4,12,28,30
This retrospective study is subject to several limitations.
Our institution is a veterans' hospital; however, this was not a
confounding factor in our study because the median age of our
PMBCL patients was relatively low. It is possible that we
enrolled patients with the disease known as “mediastinal gray-
zone lymphoma”. Mediastinal gray-zone lymphoma usually
presents with the pathological features of DLBCL and
Hodgkin disease,33 and predominantly occurs among men.34
Additional staining for PMBCL-specific transcription factors
(e.g., cREL, MAL, and FIG-1) might be used to resolve any
accidental inclusion of mediastinal gray-zone lymphoma.1
However, such staining was not performed in the present study
because of the limited number of available specimens.
Because the IELSG study has suggested that male sex is an
independent poor prognostic factor for patients with
PMBCL,12 geographic and racial differences in the sex
distribution of PMBCL may be informative and warrant
additional molecular studies to clarify the underlying patho-
genesis. Furthermore, in comparison with other reports,10,11,19ge B-cell lymphoma
od Total no. of patients No. of males % male
426 165 39
153 86 56
141 76 54
28 16 57
35 17 49
48 29 60
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received front-line HSCT, and a lower proportion of patients
who received radiotherapy. Thus, it is possible that the benefits
from front-line HSCT with CHOP-21 as the induction
chemotherapy in select patients may resemble the benefits of
induction therapy with higher-intensity chemotherapies such
as MACOP-B2 and DA-EPOCH.14 Our investigation's ability
to clearly demonstrate the benefits of radiotherapy and HSCT
may have been limited by the heterogeneity of PIT in our
patient cohort, and by the relatively small number of patients.
However, in the subset of our patients who did not receive
rituximab induction, the CR/CRu rate was relatively low,
which suggests that the prognosis of PMBCL patients was
indeed improved by radiotherapy and/or HSCT as the
consolidation or salvage therapy. In our study, one patient was
chemoresistant to salvage chemotherapy and received radio-
therapy and subsequent allogeneic HSCT; this patient
remained disease-free at the latest follow up (5 years post-
transplant), which is similar to the findings of a previously
reported study.35
In conclusion, the findings of our study demonstrate the
clinical benefits of rituximab induction in patients with
PMBCL who are treated with CHOP-21, which is the con-
ventional chemotherapy regimen. In addition, our findings
illustrate the changes to PIT that accompany rituximab in-
duction, which are characterized by an increased use of
radiotherapy. However, these changes may be partially
attributable to the use of FDG-PET evaluation. Because of the
potential for long-term sequelae, treating physicians should
carefully evaluate FDG-PET scan-positive lesions in patients
with PMBCL whenever radiotherapy is planned after ritux-
imab induction.
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